Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NovaBay Pharmaceuticals, Inc. (NBY)
|
Add to portfolio |
|
|
|
| Price: |
$0.39
| | Metrics |
| OS: |
4.21
|
M
| |
|
|
| Market cap: |
$1.64
|
M
| |
-142
|
% ROIC
|
|
Net cash:
|
$3.23
|
M
| |
$0.77
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($5.9)
|
M
| |
|
|
|
EBIT
|
($6.2)
|
M
| |
|
|
| EPS |
($6.47)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 14.4 | 10.2 | 9.9 | 6.6 | 12.5 | 18.2 | 11.9 | 4.4 |
| Revenue growth | 41.2% | 2.7% | 50.5% | -47.2% | -31.4% | 53.2% | 171.6% | 315.7% |
| Cost of goods sold | 7.6 | 4.0 | 4.4 | 1.9 | 1.5 | 2.8 | 2.5 | 1.3 |
| Gross profit | 6.8 | 6.2 | 5.6 | 4.7 | 11.0 | 15.4 | 9.4 | 3.1 |
| Gross margin | 47.4% | 60.7% | 56.2% | 71.0% | 88.0% | 84.7% | 79.3% | 71.2% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 7.8 | 8.1 | 6.2 | 8.8 | 12.8 | 13.7 | 11.8 | 10.5 |
| Research and development | 0.2 | 0.0 | 0.3 | 0.2 | 0.3 | 0.4 | 1.4 | 5.7 |
| General and administrative | 7.5 | 7.2 | 5.9 | 5.3 | 5.8 | 8.6 | 7.2 | 8.0 |
| EBITA | -7.3 | -8.8 | -6.4 | -9.4 | -7.9 | -7.3 | -10.9 | -21.1 |
| EBITA margin | -50.8% | -86.3% | -64.7% | -142.4% | -62.9% | -40.1% | -91.5% | -482.5% |
| Amortization of intangibles | 0.4 | 0.1 | | | | | | |
| EBIT | -7.7 | -8.9 | -6.4 | -9.4 | -7.9 | -7.3 | -10.9 | -21.1 |
| EBIT margin | -53.3% | -86.8% | -64.7% | -142.4% | -62.9% | -40.1% | -91.5% | -482.5% |
| Pre-tax income | -10.6 | -5.8 | -11.0 | -9.7 | -6.5 | -7.4 | -13.1 | -19.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | | | | | |
| Net income | -16.3 | -6.6 | -11.0 | -10.5 | -6.5 | -7.4 | -13.2 | -19.0 |
| Net margin | -112.9% | -64.3% | -111.1% | -158.9% | -52.3% | -40.6% | -110.5% | -433.1% |
| |
| Diluted EPS | ($10.10) | ($5.26) | ($0.31) | ($0.48) | ($0.38) | ($0.48) | ($1.40) | ($6.82) |
| Shares outstanding (diluted) | 1.6 | 1.2 | 35.1 | 21.6 | 17.1 | 15.3 | 9.4 | 2.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|